Cambridge Heart competitors

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.

Haruo Naito is a Board Member at Eisai. He has worked as Director at Eisai, President/CEO at Eisai, and Executive Vice President at Eisai. Haruo works or has worked as CHAIRMAN at The Naiito Foundation. He attended Keio University and Northwestern University.

Mark Evenstad is a Chief Executive Officer at Upsher Smith Laboratories. He works or has worked as President at Upsher Smith Laboratories.

Gary Phillips was appointed Chief Executive Officer and a member of the Pharmaxis Board of Directors in March 2013. Mr Phillips joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. He served as Commercial Director until June 2008 when he was appointed the company’s Chief Operating Officer. In this role he expanded Pharmaxis’ Commercial infrastructure in Europe and the USA, and worked closely with the clinical development, regulatory approval processes and reimbursement of Pharmaxis products Aridol and Bronchitol. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1998 to 2003, Mr. Phillips held various positions within Novartis Asia Pacific, first as a Regional Manager responsible for the P&L of 8 countries and most recently as Chief Executive Officer of Novartis Pharmaceuticals Australia Pty Ltd, where he successfully launched leading oncology and ophthalmology products and relaunched newly acquired primary care products. From 1992 to 1998, Mr. Phillips served as Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of multiple new products and achieved the leading market share amongst multinational pharmaceutical companies. Gary Phillips holds a B. Pharm. in Pharmacy with honors from Nottingham University in the U.K. and an M.B.A. from Henly Management College.